CMS-121|cas:1353224-53-9|西域试剂

CMS-121,98.30%

产品编号：Bellancom-135981| CAS NO：1353224-53-9| 分子式：C₂₀H₁₉NO₃| 分子量：321.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-135981	￥1100.00	杭州北京（现货）
Bellancom-135981	￥1800.00	杭州北京（现货）
Bellancom-135981	￥3600.00	杭州北京（现货）
Bellancom-135981	￥5800.00	杭州北京（现货）
Bellancom-135981	￥9300.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CMS-121

产品介绍

CMS-121 是一种喹诺酮衍生物，也是一种口服活性的乙酰辅酶 A 羧化酶 1 (acetyl-CoA carboxylase 1, ACC1) 抑制剂。CMS-121 分别以 EC₅₀ 值为 7 nM 和 200 nM 来保护 HT22 细胞免受缺血和氧化损伤。CMS-121 具有强大的神经保护，抗炎，抗氧化和肾保护作用。

生物活性

CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC₅₀ values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities.

体外研究

CMS-121 (1 µM; 4 hours; HT22 cells) treatment increases the phosphorylation of ACC1 at serine 79. CMS-121 can increase acetyl-CoA in cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	HT22 cells
Concentration:	1 µM
Incubation Time:	4 hours
Result:	Increases the phosphorylation of ACC1 at serine 79.

体内研究
(In Vivo)

CMS-121 (~20 mg/kg; oral administration; daily; for 4 months; female SAMP8 mice) treatment reduces cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SAMP8 mice (9 months old)
Dosage:	~20 mg/kg/day
Administration:	Oral administration; daily; for 4 months
Result:	Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SAMP8 mice (9 months old)
Dosage:	~20 mg/kg/day
Administration:	Oral administration; daily; for 4 months
Result:	Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SAMP8 mice (9 months old)
Dosage:	~20 mg/kg/day
Administration:	Oral administration; daily; for 4 months
Result:	Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (155.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1117 mL	15.5584 mL	31.1168 mL
5 mM	0.6223 mL	3.1117 mL	6.2234 mL
10 mM	0.3112 mL	1.5558 mL	3.1117 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.47 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.47 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.47 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.47 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明